Cite Filings / MLTX / 0000921895-26-001697

Feed Companies Filings Check

Sign in

SCHEDULE 13D/A

Beneficial Ownership Report

MoonLake Immunotherapeutics Filed 2026-06-29 Acc 0000921895-26-001697

Documents 1

SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X02/primary_doc.xml

Around this filing

2026-07-02 4 Chief Executive Officer sold 47,775 shares at $20.03 ($956,933)
2026-06-30 144 Sale of Securities
2026-06-29 SCHEDULE 13D/A Beneficial Ownership Report
2026-06-25 8-K Material agreement
2026-06-24 424B5 Prospectus
2026-06-23 4 Chief Financial Officer sold 39,120 shares at $22.04 ($862,205)
2026-04-02 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

External

SEC EDGAR (opens in new tab)

Loading xslSCHEDULE_13D_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…